Salvage treatment of HCV patients by Sofosbuvir, Daclatasvir, Simeprevir and Ribavirin after repeated treatment failures is associated with SVR and reduced risk of hepatocellular carcinoma

被引：0
|
作者：
Hanafy, A. [1 ]
Abd-Elsalam, S. [2 ]
Soliman, S. [3 ]
机构：
[1] Zagazig Univ, Fac Med, Internal Med Hepatol & Endoscopy Div, Zagazig, Egypt
[2] Tanta Univ, Trop Med, Tanta, Egypt
[3] Menoufia Univ, Publ Hlth, Al Minufya, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30805-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-365
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [21] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF HCV IN PATIENTS WITH SEVERE LIVER DISEASE: INTERIM RESULTS OF A MULTICENTER COMPASSIONATE USE PROGRAM
    Welzel, T. M.
    Herzer, K.
    Ferenci, P.
    Petersen, J.
    Gschwantler, M.
    Cornberg, M.
    Berg, T.
    Spengler, U.
    Weiland, O.
    Van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Ingiliz, P.
    Peck-Radosavljevic, M.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S619 - S620
  • [22] Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin
    Agarwal, Kosh
    Schultz, Michael
    Pianko, Stephen
    Bank, Leslie
    Collier, Jane
    George, Jacob
    Priest, Matthew
    Ryder, Stephen D.
    Burman, Blaire E.
    Cheent, Kuldeep
    Cramp, Matthew
    Forton, Daniel M.
    Leggett, Barbara A.
    MacQuillan, Gerry C.
    Ramji, Alnoor
    Richardson, Paul
    Ryan, Michael J.
    Stace, Nigel
    Zekry, Amany
    Zogg, Donald L.
    Barnes, Eleanor
    Brainard, Diana M.
    Massetto, Benedetta
    Chen, Frances
    McHutchison, John G.
    Subramanian, Mani
    Yoshida, Eric M.
    Foster, Graham R.
    HEPATOLOGY, 2016, 64 : 455A - 456A
  • [23] Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma
    Stemberger, M.
    Seybold, U.
    Eberle, J.
    Denk, G.
    Kolligs, F.
    Kaspar, M.
    Guba, M.
    Pichler, M.
    Spannagl, M.
    HAEMOPHILIA, 2015, 21 (02) : E131 - E133
  • [24] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH ADVANCED LIVER DISEASE: RESULTS OF A EUROPEAN COMPASSIONATE USE PROGRAM
    Welzel, T.
    Petersen, J.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S825 - S825
  • [25] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM
    Petersen, J.
    Welzel, T.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S781 - S782
  • [26] Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt
    Youssef, Aya A.
    Magdy, N.
    Hussein, Lobna A.
    El-Kosasy, A. M.
    JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2019, 57 (07) : 636 - 643
  • [27] Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin
    Korenaga, M.
    Izumi, N.
    Yokosuka, O.
    Takehara, T.
    Sakamoto, N.
    Nishiguchi, S.
    Ikeda, F.
    Yanase, M.
    Toyota, H.
    Genda, T.
    Umemura, T.
    Yatsuhashi, H.
    Ide, T.
    Toda, N.
    Nirei, K.
    Ueno, Y.
    Nishigaki, Y.
    Omata, M.
    Mizokami, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S23 - S23
  • [28] Safety and Effectiveness of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) or Ribavirin (RBV) for the Treatment of Hepatitis C Virus (HCV) Recurrence after Liver Transplant (LT)
    Lutchman, Glen A.
    Nguyen, Nghia H.
    Hsiao, Tiffany I.
    Vu, Vinh D.
    Chen, Vincent
    Ahmed, Aijaz
    Daugherty, Tami
    Garcia, Gabriel
    Kumari, Radhka
    Kim, W. Ray
    Nguyen, Mindie H.
    HEPATOLOGY, 2014, 60 : 670A - 670A
  • [29] ANTIVIRAL TREATMENT IN PATIENTS WITH ADVANCED HCV CIRRHOSIS USING SOFOSBUVIR AND LEDIPASVIR/DACLATASVIR WITH OR WITHOUT RIBAVIRIN-6 AND 12 MONTH OUTCOMES COMPARED TO UNTREATED PATIENTS
    Cheung, M. C. M.
    Foster, G. R.
    Irving, W. L.
    Walker, A. J.
    Hudson, B. E.
    Verma, S.
    McLauchlan, J.
    Mutimer, D. J.
    Brown, A.
    Gelson, W.
    MacDonald, D.
    Agarwal, K.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S185 - S186
  • [30] DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS
    Hezode, C.
    Dore, G.
    Pianko, S.
    Pol, S.
    Stuart, K.
    Thompson, A.
    Tse, E.
    Bhore, R.
    Jimenez-Exposito, M. J.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S753 - S754
12345